Enliven Therapeutics
ELVN
124 hedge funds and large institutions have $1.19B invested in Enliven Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 57 increasing their positions, 23 reducing their positions, and 20 closing their positions.
148% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 23
21% more capital invested
Capital invested by funds: $984M → $1.19B (+$208M)
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
19.31% more ownership
Funds ownership: 101.81% → 121.12% (+19%)
2% more funds holding
Funds holding: 121 → 124 (+3)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $14K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$24.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$23M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$20.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$18M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Boxer Capital Management
San Diego,
California
|
-$13.2M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$10.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.7M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$5.7M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.22M |
ELVN Hedge Fund Activity: Q2 2025 in Review
124 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q2 2025, worth a combined $1.19B — up 21% from $984M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ELVN positions and 20 closed out — a net gain of 4 holders — while 57 added to existing stakes and 23 trimmed.
The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $24.9M. The largest seller was Boxer Capital Management, exiting entirely with an estimated $13.2M sold.
- 124 institutional investors held Enliven Therapeutics (ELVN) as of Q2 2025, up from 121 in Q1 2025.
- Funds reported $1.19B of Enliven Therapeutics stock for Q2 2025, up 21% quarter-over-quarter.
- 24 funds opened new Enliven Therapeutics positions in Q2 2025 and 20 closed out, a net change of +4 holders.
- The largest Enliven Therapeutics buyer in Q2 2025 was Capital Research Global Investors, an estimated $24.9M added.
- The largest Enliven Therapeutics seller in Q2 2025 was Boxer Capital Management, an estimated $13.2M sold.
Based on aggregated 13F filings for Q2 2025.